Current approach and future perspective for ductal carcinoma in situ of the breast

por Kanbayashi, Chizuko, Iwata, Hiroji
Publicado 2017

Functions of Breast Cancer Predisposition Genes: Implications for Clinical Management

por Yoshimura, Akiyo, Imoto, Issei, Iwata, Hiroji
Publicado 2022

Real-world treatment patterns of subsequent therapy after palbociclib in patients with advanced breast cancer in Japan

por Sawaki, Masataka, Muramatsu, Yasuaki, Togo, Kanae, Iwata, Hiroji
Publicado 2023

Palbociclib as an early-line treatment for Japanese patients with hormone receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer: a review of cl...

por Masuda, Norikazu, Kosaka, Nobuyoshi, Iwata, Hiroji, Toi, Masakazu
Publicado 2021

First-line endocrine therapy for postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer: a systematic review and meta-analysis

por Shimoi, Tatsunori, Sagara, Yasuaki, Hara, Fumikata, Toyama, Tatsuya, Iwata, Hiroji
Publicado 2020

Production of Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases in Human Breast Carcinomas

por Iwata, Hiroji, Kobayashi, Shunzo, Iwase, Hirotaka, Masaoka, Akira, Fujimoto, Noboru, Okada, Yasunori
Publicado 1996

Practice management for elderly patients with breast cancer; Findings from a survey by the Japan Breast Cancer Study Group

por Sawaki, Masataka, Tamura, Kenji, Shimomura, Akihiko, Taki, Yumiko, Nagashima, Fumio, Iwata, Hiroji
Publicado 2018

Phase 1 study of oral selective estrogen receptor degrader (SERD) amcenestrant (SAR439859), in Japanese women with ER-positive and HER2-negative advanced breast cancer (AMEERA-2)

por Tamura, Kenji, Mukohara, Toru, Yonemori, Kan, Kawabata, Yumiko, Nicolas, Xavier, Tanaka, Tomoyuki, Iwata, Hiroji
Publicado 2023

Interaction of the Effects of Alcohol Drinking and Polymorphisms in Alcohol-Metabolizing Enzymes on the Risk of Female Breast Cancer in Japan

por Kawase, Takakazu, Matsuo, Keitaro, Hiraki, Akio, Suzuki, Takeshi, Watanabe, Miki, Iwata, Hiroji, Tanaka, Hideo, Tajima, Kazuo
Publicado 2009

Prospective observational study estimating willingness-to-pay for breast cancer treatments through contingent valuation method in Japanese breast cancer patients (JCOG1709A)

por Iwatani, Tsuguo, Hara, Fumikata, Shien, Tadahiko, Sasaki, Keita, Katayama, Hiroshi, Fukuda, Haruhiko, Shiroiwa, Takeru, Iwata, Hiroji
Publicado 2021

The Japanese Breast Cancer Society Clinical Practice Guidelines, 2018 edition: the tool for shared decision making between doctor and patient

por Iwata, Hiroji, Saji, Shigehira, Ikeda, Masahiko, Inokuchi, Masashi, Uematsu, Takayoshi, Toyama, Tatsuya, Horii, Rie, Yamauchi, Chikako
Publicado 2019

Correction to: The Japanese Breast Cancer Society Clinical Practice Guidelines, 2018 edition: the tool for shared decision making between doctor and patient

por Iwata, Hiroji, Saji, Shigehira, Ikeda, Masahiko, Inokuchi, Masashi, Uematsu, Takayoshi, Toyama, Tatsuya, Horii, Rie, Yamauchi, Chikako
Publicado 2021

A49T, V89L and TA repeat polymorphisms of steroid 5α-reductase type II and breast cancer risk in Japanese women

por Yang, Chunxia, Hamajima, Nobuyuki, Iwata, Hiroji, Saito, Toshiko, Matsuo, Keitaro, Hirose, Kaoru, Inoue, Manami, Takezaki, Toshiro, Tajima, Kazuo
Publicado 2002

Bone Scan Index predicts skeletal-related events in patients with metastatic breast cancer

por Idota, Ai, Sawaki, Masataka, Yoshimura, Akiyo, Hattori, Masaya, Inaba, Yoshitaka, Oze, Isao, Kikumori, Toyone, Kodera, Yasuhiro, Iwata, Hiroji
Publicado 2016

Correction to: Phase I dose-finding study of eribulin and capecitabine for metastatic breast cancer: JBCRG-18 cape study

por Hattori, Masaya, Ishiguro, Hiroshi, Masuda, Norikazu, Yoshimura, Akiyo, Ohtani, Shoichiro, Yasojima, Hiroyuki, Morita, Satoshi, Ohno, Shinji, Iwata, Hiroji
Publicado 2017

Phase I dose-finding study of eribulin and capecitabine for metastatic breast cancer: JBCRG-18 cape study

por Hattori, Masaya, Ishiguro, Hiroshi, Masuda, Norikazu, Yoshimura, Akiyo, Ohtani, Shoichiro, Yasojima, Hiroyuki, Morita, Satoshi, Ohno, Shinji, Iwata, Hiroji
Publicado 2017

Rainbow of KIBOU (ROK) study: a Breast Cancer Survivor Cohort in Japan

por Mizota, Yuri, Ohashi, Yasuo, Iwase, Takuji, Iwata, Hiroji, Sawaki, Masataka, Kinoshita, Takayuki, Taira, Naruto, Mukai, Hirofumi, Yamamoto, Seiichiro
Publicado 2017

Estrogen Receptor, c‐erbB‐2 and nm23/NDP Kinase Expression in the Intraductal and Invasive Components of Human Breast Cancers

por Kobayashi, Shunzo, Iwase, Hirotaka, Itoh, Yukashi, Fukuoka, Hideki, Yamashita, Hiroko, Kuzushima, Tatsuya, Iwata, Hiroji, Masaoka, Akira, Kimura, Narimichi
Publicado 1992

Subgroup analysis of Japanese patients in a Phase 3 study of atezolizumab in advanced triple-negative breast cancer (IMpassion130)

por Iwata, Hiroji, Inoue, Kenichi, Kaneko, Koji, Ito, Yoshinori, Tsugawa, Koichiro, Hasegawa, Ayumi, Nakagawa, Shintaro, Kuratomi, Hiroyasu, Tamura, Kenji
Publicado 2019

Corrigendum to: Subgroup analysis of Japanese patients in a Phase 3 study of atezolizumab in advanced triple-negative breast cancer (IMpassion130)

por Iwata, Hiroji, Inoue, Kenichi, Kaneko, Koji, Ito, Yoshinori, Tsugawa, Koichiro, Hasegawa, Ayumi, Nakagawa, Shintaro, Kuratomi, Hiroyasu, Tamura, Kenji
Publicado 2020